AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
Exploring BTK degraders and their potential in heavily pretreated CLL patients
This chapter explores the creation of BTK degraders, a novel class of drugs designed to bind to and degrade BTK and its scaffolding. Early phase clinical trial data from Nurex and Biogenes revealed promising results in heavily treated patients, with response rates reaching 70% in post-covalent BTK-treated patients.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode